Genetic Technologies (GTG) is collaborating with Obstetrics and Gynaecology practice Siles Health to implement the geneType Multi-Risk Test.
The geneType Multi-Risk Test has been designed to identify an individual’s risk of developing various common serious diseases.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It identifies the sporadic (non-inherited) risk that accounts for up to 85% of diagnosed cases of diseases that include ovarian cancer, type 2 diabetes, prostate cancer, colorectal cancer, breast cancer and coronary artery disease.
Knowing the risk of developing a disease allows the patient and their healthcare provider to put together a personalised preventive health plan.
As part of the collaboration, the geneType Multi-Risk Test will be implemented in nine Obstetrics and Gynaecology clinics belonging to Siles Health, a company that treats more than 15,000 patients each year.
GTG CEO Simon Morriss said: “Adoption of geneType Multi-Risk Test by Siles Health provides GTG with immediate access to an important and expanding group of patients, with the opportunity to make a significant improvement in their health outcomes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This partnership also represents another significant milestone along our pathway, the successful commercialisation of geneType Multi-Risk Tests.”
Siles Health will provide a dedicated in-house genetic counselling service to create personalised preventative pathways for patients that are identified as having a high risk of developing a disease.
The company will also refer patients to physicians that can provide dedicated genetic counselling support.
Siles Health founder Charles Siles said: “geneType Multi-Risk Test is a critical risk identification tool to assist our practice to identify potentially high-risk patients and develop truly actionable, personalised, preventative health plans.”
GTG stated that the partnership deal provides a framework for establishing a consistent standard of care for physicians and patients for the test.
